全文获取类型
收费全文 | 2279篇 |
免费 | 149篇 |
国内免费 | 53篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 49篇 |
妇产科学 | 84篇 |
基础医学 | 162篇 |
口腔科学 | 24篇 |
临床医学 | 359篇 |
内科学 | 453篇 |
皮肤病学 | 57篇 |
神经病学 | 129篇 |
特种医学 | 19篇 |
外科学 | 160篇 |
综合类 | 103篇 |
预防医学 | 98篇 |
眼科学 | 19篇 |
药学 | 269篇 |
1篇 | |
中国医学 | 95篇 |
肿瘤学 | 395篇 |
出版年
2024年 | 7篇 |
2023年 | 80篇 |
2022年 | 130篇 |
2021年 | 149篇 |
2020年 | 137篇 |
2019年 | 182篇 |
2018年 | 139篇 |
2017年 | 143篇 |
2016年 | 120篇 |
2015年 | 101篇 |
2014年 | 182篇 |
2013年 | 303篇 |
2012年 | 107篇 |
2011年 | 120篇 |
2010年 | 64篇 |
2009年 | 82篇 |
2008年 | 79篇 |
2007年 | 66篇 |
2006年 | 61篇 |
2005年 | 50篇 |
2004年 | 34篇 |
2003年 | 35篇 |
2002年 | 31篇 |
2001年 | 15篇 |
2000年 | 13篇 |
1999年 | 16篇 |
1998年 | 10篇 |
1997年 | 4篇 |
1996年 | 1篇 |
1995年 | 4篇 |
1994年 | 2篇 |
1993年 | 1篇 |
1992年 | 2篇 |
1991年 | 1篇 |
1990年 | 1篇 |
1989年 | 1篇 |
1987年 | 1篇 |
1986年 | 1篇 |
1985年 | 2篇 |
1983年 | 2篇 |
1981年 | 1篇 |
1971年 | 1篇 |
排序方式: 共有2481条查询结果,搜索用时 9 毫秒
991.
《结合医学学报(英文版)》2022,20(2):135-144
BackgroundBeginning with the concepts of stress developed by Selye, an approach to stress and pain management, known as neuro-emotional technique (NET), has been developed. It is a treatment approach based on the principle that the stressor effects of dormant and/or current unresolved issues or trauma are what determine one’s bodily responses. These responses are relatively personalized to the conditioned, experiential and emotional reality of the individual.ObjectiveTo determine the effect of NET on patients with chronic low back pain (CLBP) over time.Design, setting, participants, and interventionsIn a randomized, double-blinded, placebo-controlled study conducted in a single clinic, NET or control treatments were given twice weekly for 4 weeks in a population of 112 patients.Main outcome measuresOutcome measures, including Oswestry Disability Index, Quadruple Visual Analogue Scale, the psychoneuroimmunology markers of blood serum levels of C-reactive protein, tumour necrosis factor-α, interleukin-1 (IL-1), IL-6, and IL-10, and 10 dimensions of the Short Form Health Survey scale, were assessed at baseline and at 1, 3 and 6 months following the intervention period.ResultsCompared to placebo, NET produced clinical and statistical significance (P < 0.001) via declines of virtually all physiological, pain and disability markers, accompanied by gains in quality-of-life indicators at 0 (baseline), 1, 3 and 6 months. Reductions of the percentages of patients whose 5 biomarkers lay outside the normative range were achieved at 1, 3 and 6 months by NET but not control interventions.ConclusionA randomized, controlled trial of CLBP patients indicated that 8 NET interventions, compared to placebo, produced clinically and statistically significant reductions in pain, disability and inflammatory biomarkers, and improvements in quality-of-life measures.Trial registrationThe trial was registered with the Australian and New Zealand Clinical Trials Registry (No. ACTRN12608000002381). 相似文献
992.
Stewart J. Tepper Juanzhi Fang Pamela Vo Ying Shen Lujia Zhou Ahmad Abdrabboh Mrudula Glassberg Matias Ferraris 《The journal of headache and pain》2021,22(1)
BackgroundMigraine is one of the leading causes of disability worldwide. Erenumab is a fully human monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor. This study aimed to evaluate real-world evidence on the impact of erenumab on acute medication usage and health care resource utilization (HCRU) among migraine patients.MethodsThis retrospective effectiveness study utilized the US Optum’s de-identified Clinformatics® Data Mart database to identify migraine patients initiating erenumab between May 1, 2018 and September 30, 2019. Patients had to be at least 18 years old, with a minimum of three doses for erenumab in the 6-month post-index period and continuous medical/pharmacy coverage in the 12-month pre- and 6-month post-index period. The date of the first claim for erenumab served as the index date. Use of acute medications overall and at different drug class level, and HCRU were compared during the 6-month pre- vs. post-index period. Impact of erenumab on a composite endpoint of three possible events: 1) outpatient visit with a diagnosis of migraine and an associated acute medication claim within 7 days of the visit, 2) hospital admission with a primary diagnosis for migraine, or 3) emergency room visit with a primary diagnosis for migraine (any events that occurred ≤3 days apart were counted only once) was also evaluated.ResultsThe analysis included 3171 identified patients. At 6 months, following initiation of erenumab, acute medication use including the number of types of acute medication, number of claims of each medication and % of patients who received acute medication, and HCRU were significantly decreased. For the composite outcome, the mean number of events decreased from 1.03 to 0.77 (rate ratio: 0.75; 95% CI: 0.71 to 0.79; P < 0.0001). A decrease in the proportion of patients with any of the three events was also observed (52.7% vs. 39.5%, P < 0.0001).ConclusionIn this retrospective analysis, erenumab was associated with significantly reduced acute medication use and HCRU in a real-world setting, hence significantly reducing the burden of the disease. A composite endpoint could be used as a proxy to evaluate the burden of migraine attacks; however, further research is needed.Supplementary InformationThe online version contains supplementary material available at 10.1186/s10194-021-01238-2. 相似文献
993.
994.
995.
As the news of approval of COVID-19 vaccination emerge, neurologists across the globe ponder upon whether to use immunotherapies in patients with Multiple Sclerosis (MS). This paper highlights the mechanism of various disease modifying therapies (DMTs) as well as the recently approved Pfizer and Moderna vaccines for COVID-19 as well as guidelines as introduced by National Multiple Sclerosis Society. As their mechanisms counteract each other at the molecular level, we believe further evidence and data might lay the foundation to formulate much needed recommendations for the usage of these medications while vaccinating MS patients on DMTs. 相似文献
996.
997.
998.
Monica Rosales Santillan Peyton C. Morss Martina L. Porter 《Expert opinion on biological therapy》2020,20(6):621-633
ABSTRACTIntroduction: Hidradenitis suppurativa (HS) is a chronic skin disorder characterized by inflammatory nodules, abscesses, and fistulae. Patients tend to present in young adulthood and are predominantly female. The pathogenesis of HS involves apopilosebaceous gland follicle occlusion and affected areas often occur where this type of gland predominates. Treatment selection depends on HS severity, which is included in different scoring systems. In recent years, biological therapies have been evaluated and used with increasing frequency in moderate-to-severe HS disease.Areas covered: This review focuses on biological therapies for HS as assessed in case reports, case series, and clinical trials. The efficacy, hidradenitis suppurativa scoring systems, and long-term results of these therapies are discussed depending on the studies’ endpoints.Expert opinion: Adalimumab is currently the only FDA-approved HS biological therapy. Some patients do not experience treatment efficacy with adalimumab at 40 mg/week, which may result in increasing the dose or seeking other treatments. Infliximab is the next line of HS treatment with demonstrated efficacy. Other biological therapies being studied have demonstrated efficacy in small patient groups, but lack study power. Further studies may provide answers to seeking treatment options for patients who fail to improve on current standard HS treatment. 相似文献
999.
1000.
《Archives of Cardiovascular Diseases》2020,113(3):223